CHARLOTTE, N.C.—Immune checkpoint inhibitors have become an important part of the armamentarium in the treatment of advanced malignancies, but their use is associated with hepatotoxicity. A recent study has identified the risk factors most strongly associated with this adverse event.
To determine the predictors of immune checkpoint inhibitor (ICPI)-induced hepatotoxicity, researchers from Cleveland Clinic mined the IBM Explorys database—which includes electronic health record data